KR20140141666A - 흉선 기질 림프구형성소를 결합할 수 있는 항원 결합 단백질 - Google Patents

흉선 기질 림프구형성소를 결합할 수 있는 항원 결합 단백질 Download PDF

Info

Publication number
KR20140141666A
KR20140141666A KR20147029417A KR20147029417A KR20140141666A KR 20140141666 A KR20140141666 A KR 20140141666A KR 20147029417 A KR20147029417 A KR 20147029417A KR 20147029417 A KR20147029417 A KR 20147029417A KR 20140141666 A KR20140141666 A KR 20140141666A
Authority
KR
South Korea
Prior art keywords
tslp
antibody
antibodies
antigen binding
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR20147029417A
Other languages
English (en)
Korean (ko)
Inventor
마이클 알. 코머우
제임스 에프. 스모더스
보-린 피. 윤
크리스토퍼 메린
Original Assignee
암젠 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40242598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20140141666(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 암젠 인코퍼레이티드 filed Critical 암젠 인코퍼레이티드
Publication of KR20140141666A publication Critical patent/KR20140141666A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR20147029417A 2007-09-10 2008-09-09 흉선 기질 림프구형성소를 결합할 수 있는 항원 결합 단백질 Ceased KR20140141666A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97117807P 2007-09-10 2007-09-10
US60/971,178 2007-09-10
US9167608P 2008-08-25 2008-08-25
US61/091,676 2008-08-25
PCT/US2008/010510 WO2009035577A1 (en) 2007-09-10 2008-09-09 Antigen binding proteins capable of binding thymic stromal lymphopoietin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020107007193A Division KR101597371B1 (ko) 2007-09-10 2008-09-09 흉선 기질 림프구형성소를 결합할 수 있는 항원 결합 단백질

Publications (1)

Publication Number Publication Date
KR20140141666A true KR20140141666A (ko) 2014-12-10

Family

ID=40242598

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107007193A Active KR101597371B1 (ko) 2007-09-10 2008-09-09 흉선 기질 림프구형성소를 결합할 수 있는 항원 결합 단백질
KR20147029417A Ceased KR20140141666A (ko) 2007-09-10 2008-09-09 흉선 기질 림프구형성소를 결합할 수 있는 항원 결합 단백질

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020107007193A Active KR101597371B1 (ko) 2007-09-10 2008-09-09 흉선 기질 림프구형성소를 결합할 수 있는 항원 결합 단백질

Country Status (36)

Country Link
US (6) US7982016B2 (enExample)
EP (3) EP2703414A1 (enExample)
JP (8) JP5956716B2 (enExample)
KR (2) KR101597371B1 (enExample)
CN (2) CN101809035B (enExample)
AR (1) AR068508A1 (enExample)
AU (1) AU2008300028B2 (enExample)
CA (1) CA2698382C (enExample)
CL (2) CL2008002668A1 (enExample)
CR (2) CR11319A (enExample)
CY (2) CY1117702T1 (enExample)
DK (1) DK2205635T3 (enExample)
EA (2) EA201590631A1 (enExample)
ES (1) ES2581229T3 (enExample)
FR (1) FR22C1059I2 (enExample)
HR (1) HRP20160638T1 (enExample)
HU (2) HUE028361T2 (enExample)
IL (3) IL204069A (enExample)
JO (1) JO3351B1 (enExample)
LT (2) LT2205635T (enExample)
LU (1) LUC00289I2 (enExample)
MX (1) MX2010002590A (enExample)
MY (1) MY150242A (enExample)
NL (1) NL301207I2 (enExample)
NO (1) NO2022055I1 (enExample)
NZ (1) NZ583933A (enExample)
PE (2) PE20110668A1 (enExample)
PH (1) PH12017501025B1 (enExample)
PL (1) PL2205635T3 (enExample)
PT (1) PT2205635T (enExample)
RS (1) RS54950B1 (enExample)
SG (2) SG10201506251YA (enExample)
SI (1) SI2205635T1 (enExample)
TW (2) TWI449709B (enExample)
WO (1) WO2009035577A1 (enExample)
ZA (1) ZA201001895B (enExample)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
AU2007334499B2 (en) 2006-12-14 2014-04-24 Merck Sharp & Dohme Corp. Engineered anti-TSLP antibody
US9175078B2 (en) * 2008-01-25 2015-11-03 Amgen Inc. Ferroportin antibodies and methods of use
WO2011056772A1 (en) * 2009-11-04 2011-05-12 Schering Corporation Engineered anti-tslp antibody
EP2725034B1 (en) * 2010-09-22 2019-04-03 Amgen Inc. Carrier immunoglobulins with no specificity for human tissues and uses thereof
US9732151B2 (en) * 2011-11-03 2017-08-15 Merck Sharp & Dohme Corp. Biomarkers for TSLP treatment
DK2841456T3 (en) * 2012-04-27 2018-08-13 Novo Nordisk As HUMAN CD30 LIGAND ANTI-BINDING PROTEINS
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP3041863A4 (en) 2013-09-05 2017-08-16 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
WO2015118124A1 (en) * 2014-02-06 2015-08-13 Vib Vzw Thymic stromal lymphopoietin receptor antagonist
KR102496507B1 (ko) 2014-05-07 2023-02-03 암겐 인코포레이티드 충격 감소 요소들을 가진 자동 주사기
CA2949237C (en) 2014-05-16 2022-08-23 Amgen Inc. Assay for detecting th1 and th2 cell populations
KR20220143782A (ko) 2014-06-03 2022-10-25 암겐 인코포레이티드 약물 전달 디바이스의 사용자를 보조하기 위한 디바이스들 및 방법들
MX2021014323A (es) 2014-10-14 2023-02-02 Amgen Inc Dispositivo de inyección de fármaco con indicadores visuales y audibles.
CN114569716A (zh) 2014-10-23 2022-06-03 美国安进公司 降低药物制剂的粘度
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
CA3069716C (en) 2015-02-17 2021-11-09 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
US11806509B2 (en) 2015-02-27 2023-11-07 Amgen Inc. Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
WO2016142426A1 (en) * 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited Tslp binding proteins
CN107849148B (zh) * 2015-05-21 2023-09-19 哈普恩治疗公司 三特异性结合蛋白质及使用方法
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
WO2017042701A1 (en) * 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
EP3347377B1 (en) 2015-09-09 2021-02-17 Novartis AG Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
EP3386573B1 (en) 2015-12-09 2019-10-02 Amgen Inc. Auto-injector with signaling cap
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
MA43660A (fr) 2016-01-22 2018-11-28 Adimab Llc Anticorps anti-facteur xi de coagulation
GB201615588D0 (en) * 2016-09-14 2016-10-26 Glaxosmithkline Ip Dev Ltd TSLP Binding Proteins
DK3429663T3 (da) 2016-03-15 2020-09-28 Amgen Inc Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
AU2017247966B2 (en) * 2016-04-05 2020-10-22 Universiteit Gent Novel TSLP inhibitors
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
WO2017197222A1 (en) 2016-05-13 2017-11-16 Amgen Inc. Vial sleeve assembly
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
TWI752964B (zh) 2016-06-14 2022-01-21 美商默沙東藥廠 抗凝血因子ｘｉ抗體
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
JP6925421B2 (ja) * 2016-08-05 2021-08-25 ワイ−バイオロジクス・インコーポレイテッド プログラム化された細胞死蛋白質リガンド−１（ｐｄ−ｌ１）に対する抗体及びその用途
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
EP3532127A1 (en) 2016-10-25 2019-09-04 Amgen Inc. On-body injector
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
JP2020503976A (ja) 2017-01-17 2020-02-06 アムジエン・インコーポレーテツド 注入デバイスならびに関連する使用および組立方法
EA201991099A1 (ru) 2017-01-24 2020-03-23 Ай-Маб Биофарма Юэс Лимитед Антитела против cd73 и их применение
CA3048520A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
EP3582829A1 (en) 2017-02-17 2019-12-25 Amgen Inc. Insertion mechanism for drug delivery device
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
JP2020508803A (ja) 2017-03-06 2020-03-26 アムジエン・インコーポレーテツド 作動防止特徴部を備える薬物送達デバイス
US11571511B2 (en) 2017-03-07 2023-02-07 Amgen Inc. Insertion mechanism and method of inserting a needle of a drug delivery device
KR102893480B1 (ko) 2017-03-09 2025-11-28 암겐 인코포레이티드 약물 전달 장치용 삽입 메커니즘
CA3056011A1 (en) 2017-03-14 2018-09-20 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
HUE063805T2 (hu) 2017-03-28 2024-01-28 Amgen Inc Dugattyúrúd és fecskendõ összeállító rendszer és eljárás
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
US12103979B2 (en) 2017-04-28 2024-10-01 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
AU2018282077B2 (en) 2017-06-08 2023-11-23 Amgen Inc. Torque driven drug delivery device
CA3061982A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
MA49447A (fr) 2017-06-22 2020-04-29 Amgen Inc Réduction des impacts/chocs d'activation d'un dispositif
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
CN109206514B (zh) * 2017-07-03 2019-10-08 拜西欧斯（北京）生物技术有限公司 Tslp单克隆抗体及其制备方法和应用
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
MA49626A (fr) 2017-07-21 2020-05-27 Amgen Inc Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
WO2019022950A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF
JP2020528296A (ja) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
EA202090380A1 (ru) 2017-08-01 2020-05-21 Эмджен Инк. Системы и способы для выполнения анализа гликанов в образце в режиме реального времени
IL271499B2 (en) 2017-08-01 2024-12-01 Amgen Inc Systems and methods for real-time polypeptide sample preparation for mass spectrometry analysis
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
EP3669004A1 (en) 2017-08-16 2020-06-24 Medimmune, LLC Compositions and methods for treatment of atopic dermatitis and treatment selection
US11077246B2 (en) 2017-08-18 2021-08-03 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
ES2939292T3 (es) 2017-10-04 2023-04-20 Amgen Inc Adaptador de flujo para dispositivo de administración de fármacos
EP3691716B1 (en) 2017-10-06 2023-11-29 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
US11464903B2 (en) 2017-10-09 2022-10-11 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
KR102425983B1 (ko) 2017-10-13 2022-07-29 하푼 테라퓨틱스, 인크. 삼중특이적 단백질 및 사용 방법
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
WO2019090079A1 (en) 2017-11-03 2019-05-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
JP2021501616A (ja) 2017-11-06 2021-01-21 アムジエン・インコーポレーテツド 配置及び流量検出を備える薬物送達デバイス
US12053618B2 (en) 2017-11-06 2024-08-06 Amgen Inc. Fill-finish assemblies and related methods
MA50557A (fr) 2017-11-10 2020-09-16 Amgen Inc Pistons pour dispositifs d'administration de médicament
IL273638B2 (en) 2017-11-16 2024-10-01 Amgen Inc Door latch mechanism for drug delivery device
US12405275B2 (en) 2018-03-13 2025-09-02 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
KR102775717B1 (ko) 2018-03-13 2025-03-06 암젠 인크 질량 분광 분석을 위한 폴리펩티드의 순차적 소화
CN111954719B (zh) 2018-03-26 2025-07-18 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
KR20210020903A (ko) 2018-05-14 2021-02-24 하푼 테라퓨틱스, 인크. 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
CA3103682A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
MA53379A (fr) 2018-07-24 2021-06-02 Amgen Inc Dispositifs d'administration pour l'administration de médicaments
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
MA53320A (fr) 2018-07-31 2021-11-03 Amgen Inc Ensemble de trajet de fluide pour dispositif d'administration de médicament
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
AU2019347710B2 (en) 2018-09-24 2025-05-08 Amgen Inc. Interventional dosing systems and methods
IL281683B2 (en) 2018-09-25 2023-04-01 Harpoon Therapeutics Inc dll3 binding proteins and methods of use
IL281469B2 (en) 2018-09-28 2024-08-01 Amgen Inc Muscle wire escapement activation assembly for a drug delivery device
US12156991B2 (en) 2018-10-02 2024-12-03 Amgen Inc. Injection systems for drug delivery with internal force transmission
WO2020072846A1 (en) 2018-10-05 2020-04-09 Amgen Inc. Drug delivery device having dose indicator
WO2020081480A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Platform assembly process for drug delivery device
US12053617B2 (en) 2018-10-15 2024-08-06 Amgen Inc. Drug delivery device having damping mechanism
US12485219B2 (en) 2018-11-01 2025-12-02 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI852964B (zh) 2018-12-14 2024-08-21 美商安進公司 與依照斜率的蛋白質濃度確定一起使用之系統適用性方法
WO2020142693A1 (en) * 2019-01-04 2020-07-09 Empirico Inc. Treatment of thymic stromal lymphopoietin (tslp) related diseases by inhibition of long-form tslp transcripts
ES2987091T3 (es) 2019-02-14 2024-11-13 Amgen Inc Sistemas y métodos para preparar una muestra y realizar un ensayo en tiempo real de la muestra
JP7530376B2 (ja) 2019-02-20 2024-08-07 アムジエン・インコーポレーテツド タンパク質の安定性を決定する方法
JP7570341B2 (ja) 2019-03-04 2024-10-21 アムジエン・インコーポレーテツド 高分子量種のインビボでの可逆性
EP3948242A1 (en) 2019-03-27 2022-02-09 Amgen Inc. Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
ES3032751T3 (en) 2019-04-24 2025-07-24 Amgen Inc Syringe sterilization verification assemblies and methods
TW202110882A (zh) 2019-06-04 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 能結合胸腺基質淋巴細胞生成素的抗體及其應用
MA56121A (fr) 2019-06-05 2022-04-13 Amgen Inc Procédés d'identification d'attributs de protéines thérapeutiques
AU2020311432A1 (en) 2019-07-11 2022-02-03 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
MX2022002149A (es) 2019-08-23 2022-03-17 Amgen Inc Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados.
BR112022005583A2 (pt) 2019-09-26 2022-09-20 Amgen Inc Métodos para a produção de composições de anticorpos
RS66646B1 (sr) 2019-10-28 2025-04-30 Medimmune Ltd Formulacije suvog praška vezujućih antitela za timusni stromalni limfopoetin (tslp) i postupci njihove upotrebe
CN112876564B (zh) * 2019-11-29 2022-07-15 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
US20220363781A1 (en) * 2019-12-13 2022-11-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-tslp antibody and uses thereof
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN111171150B (zh) * 2020-02-05 2020-12-08 北京智仁美博生物科技有限公司 抗人tslp抗体及其用途
WO2021163588A1 (en) 2020-02-13 2021-08-19 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
CN115279404A (zh) 2020-02-13 2022-11-01 安进公司 人抗tslp抗体的配制品及治疗炎性疾病的方法
MX2022010120A (es) 2020-02-18 2022-09-05 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos.
CN111662379B (zh) * 2020-05-09 2021-03-02 江苏省疾病预防控制中心(江苏省公共卫生研究院) 抗新型冠状病毒的抗体、制备方法和应用
EP4153625A4 (en) * 2020-05-20 2024-09-25 The Trustees Of Columbia University In The City Of New York STRONG NEUTRALISING ANTIBODIES AGAINST SARS-COV-2, THEIR PRODUCTION AND USE
EP4162257A1 (en) 2020-06-04 2023-04-12 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
AU2021343495A1 (en) 2020-09-18 2023-04-27 Amgen Inc. Methods of processing a sample for peptide mapping analysis
KR20230087539A (ko) 2020-10-15 2023-06-16 암젠 인크 항체 생산 방법에서의 상대적인 비결합 글리칸
WO2022098595A1 (en) 2020-11-05 2022-05-12 Amgen Inc. Materials and methods for protein processing
CN114437212B (zh) * 2020-11-06 2023-03-14 上海麦济生物技术有限公司 抗人胸腺基质淋巴细胞生成素抗体及其制备方法和应用
TW202229339A (zh) * 2020-12-03 2022-08-01 大陸商江蘇恒瑞醫藥股份有限公司 結合胸腺基質淋巴細胞生成素的抗體及其應用
CN113501878B (zh) 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN115210258A (zh) * 2021-02-04 2022-10-18 舒泰神（北京）生物制药股份有限公司 特异性识别胸腺基质淋巴细胞生成素的抗体及其用途
BR112023022041A2 (pt) 2021-04-23 2023-12-26 Amgen Inc Anticorpos anti-tslp modificados
EP4326766A1 (en) 2021-04-23 2024-02-28 Amgen Inc. Anti-tslp antibody compositions and uses thereof
KR20240011135A (ko) 2021-05-21 2024-01-25 암젠 인크 약물 용기를 위한 충전 레시피를 최적화하는 방법
WO2022254428A2 (en) * 2021-05-30 2022-12-08 Biolojic Design Ltd. Engineered dual binding antibodies and uses thereof
CN113069543B (zh) * 2021-06-07 2021-08-06 迈威(上海)生物科技股份有限公司 包含抗胸腺基质淋巴细胞生成素的单克隆抗体的液体组合物
TW202317614A (zh) 2021-06-07 2023-05-01 美商安進公司 使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023070948A1 (zh) * 2021-11-01 2023-05-04 江苏荃信生物医药股份有限公司 包含抗人胸腺基质淋巴细胞生成素(tslp)单克隆抗体的浓缩溶液的制备方法及液体制剂
WO2023086793A1 (en) 2021-11-09 2023-05-19 Amgen Inc. Production of therapeutic proteins
CN117106084B (zh) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN114369654B (zh) * 2021-12-21 2023-11-07 广州市妇女儿童医疗中心 川崎病的生物标志物及其应用
KR20240128709A (ko) * 2021-12-24 2024-08-26 인매진 피티이. 엘티디. 신규한 항-tslp 항체
WO2023166420A1 (en) * 2022-03-03 2023-09-07 Pfizer Inc. Multispecific antibodies and uses thereof
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
US12110324B2 (en) * 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
CN118772267B (zh) * 2022-10-21 2025-05-13 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
UY40500A (es) 2022-10-26 2024-04-30 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas
TW202448501A (zh) 2023-02-02 2024-12-16 美商麥迪紐有限責任公司 用抗ｔｓｌｐ抗體治療慢性鼻竇炎
CN120659807A (zh) * 2023-02-23 2025-09-16 四川科伦博泰生物医药股份有限公司 一种靶向tslp的单克隆抗体制剂
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
TW202509066A (zh) 2023-05-18 2025-03-01 美商麥迪紐有限責任公司 用抗ｔｓｌｐ抗體治療皮質類固醇依賴性氣喘
WO2024259275A1 (en) 2023-06-14 2024-12-19 Bristol-Myers Squibb Company Near real time sialic acid quantitation of glycoproteins
WO2024264002A2 (en) * 2023-06-22 2024-12-26 Paragon Therapeutics, Inc. Antibodies that bind tslp and tslpr and methods of use
WO2024264003A2 (en) * 2023-06-22 2024-12-26 Paragon Therapeutics, Inc. Antibodies that bind interleukin 13 and tslp or tslpr and methods of use
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途
WO2025077822A1 (en) * 2023-10-12 2025-04-17 Innovent Biologics (Suzhou) Co., Ltd. Anti-tslp antibodies and uses thereof
WO2025101602A1 (en) 2023-11-07 2025-05-15 Amgen Inc. Methods of analyzing amino acid content of a therapeutic protein
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025147632A1 (en) 2024-01-05 2025-07-10 Medimmune, Llc Treatment of chronic obstructive pulmonary disease with anti-tslp antibody
WO2025221247A1 (en) 2024-04-17 2025-10-23 Amgen Inc. Treatment of eosinophilic esophagitis with anti-tslp antibody
WO2025255028A1 (en) 2024-06-03 2025-12-11 Amgen Inc. High-throughput liquid chromatography-mass spectrometry-based peptide mapping

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
JPS58117537A (ja) 1982-01-06 1983-07-13 Toray Ind Inc 感光性樹脂組成物
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990015870A1 (en) 1989-06-15 1990-12-27 Immunex Corporation Interleukin-7 receptors
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
DE69327582T2 (de) 1992-04-30 2000-08-03 Amgen Inc., Thousand Oaks Methoden zur Behandlung von Interleukin- 1 und - Tumor - Nekrose - Faktor - verursachten Krankheiten
EP0672141B1 (en) 1992-10-23 2003-05-14 Immunex Corporation Methods of preparing soluble, oligomeric proteins
EP0737071A1 (en) 1993-06-15 1996-10-16 Il- Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
GB9702944D0 (en) 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
DE69943022D1 (de) 1998-03-19 2011-01-20 Human Genome Sciences Rockville Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
US6844170B1 (en) * 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US20030099947A1 (en) 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
EP2314696A1 (en) 1998-09-21 2011-04-27 Schering Corporation Therapeutic uses of human Interleukin-B50 antagonist.
ES2288036T5 (es) * 1998-11-13 2017-07-06 Immunex Corporation ADN de TSLP humano y polipéptidos
AU2396600A (en) 1998-12-30 2000-07-31 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
EP2329842A3 (en) 2000-05-12 2011-07-27 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
US7964713B2 (en) 2000-06-28 2011-06-21 Amgen Inc. Nucleic acid molecules encoding thymic stromal lympopoietin receptor proteins and a process for producing the encoded polypeptides thereof
WO2002000723A2 (en) 2000-06-28 2002-01-03 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CN1234728C (zh) * 2001-05-16 2006-01-04 上海睿星基因技术有限公司 新的人淋巴因子、其编码序列及用途
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
US7288633B2 (en) 2001-07-23 2007-10-30 Immunex Corporation Modified human thymic stromal lymphopoietin
EP1487865A4 (en) * 2002-02-01 2005-12-14 Schering Corp USE OF CYTOKIN RELATED REAGENTS OF MAMMALS
HRP20020453A2 (en) 2002-05-23 2003-12-31 Pliva D D 1,3-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
US7438910B2 (en) 2002-09-06 2008-10-21 Amgen Inc. Therapeutic human anti-IL1-R1 monoclonal antibody
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
AU2004257781B2 (en) 2003-07-18 2009-07-16 Merck Sharp & Dohme Corp. Treatment and diagnosis of neoplasms using Thymic Stromal Lymphopoietin
AR042955A1 (es) 2003-07-18 2005-07-13 Amgen Inc Agentes de union especifica al factor de crecimiento de hepatocitos
EP2275448A3 (en) 2003-12-19 2013-02-06 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
CA2577631A1 (en) 2004-08-20 2006-03-02 Amgen Inc. Methods and compositions for treating allergic inflammation
JP2008520684A (ja) * 2004-11-17 2008-06-19 アブジェニックス・インコーポレーテッド Ｉｌ−１３に対する完全ヒトモノクローナル抗体
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
CN101370831B (zh) 2006-01-13 2013-06-19 Irm责任有限公司 用于治疗过敏性疾病的针对胸腺基质淋巴细胞生成素受体的抗体
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
AU2007334499B2 (en) 2006-12-14 2014-04-24 Merck Sharp & Dohme Corp. Engineered anti-TSLP antibody
PE20090768A1 (es) 2007-06-20 2009-07-09 Irm Llc Metodos y composiciones para el tratamiento de enfermedades alergicas
JP5782185B2 (ja) 2012-06-01 2015-09-24 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
AU2008300028A1 (en) 2009-03-19
CY2022036I1 (el) 2023-01-05
NZ583933A (en) 2012-07-27
JO3351B1 (ar) 2019-03-13
JP2017110011A (ja) 2017-06-22
CA2698382A1 (en) 2009-03-19
US20090238823A1 (en) 2009-09-24
JP2020058365A (ja) 2020-04-16
PH12017501025B1 (en) 2022-10-26
SG10201506251YA (en) 2015-11-27
IL204069A (en) 2017-03-30
PT2205635T (pt) 2016-07-13
US20160152700A1 (en) 2016-06-02
RS54950B1 (sr) 2016-11-30
LTC2205635I2 (enExample) 2025-10-27
KR101597371B1 (ko) 2016-02-26
US9284372B2 (en) 2016-03-15
US7982016B2 (en) 2011-07-19
JP2023065375A (ja) 2023-05-12
CN104231081A (zh) 2014-12-24
CN101809035B (zh) 2014-07-09
US20120190829A1 (en) 2012-07-26
JP2021191758A (ja) 2021-12-16
ES2581229T3 (es) 2016-09-02
US20110274687A1 (en) 2011-11-10
ZA201001895B (en) 2011-02-23
PE20140232A1 (es) 2014-02-28
IL265854A (en) 2019-06-30
PE20110668A1 (es) 2011-10-01
HUS2200051I1 (hu) 2022-12-28
TWI449709B (zh) 2014-08-21
CR20150095A (es) 2015-04-06
US8163284B2 (en) 2012-04-24
HRP20160638T1 (hr) 2016-07-01
US20200071393A1 (en) 2020-03-05
IL250900A0 (en) 2017-04-30
MX2010002590A (es) 2010-03-26
JP2010538608A (ja) 2010-12-16
NL301207I2 (nl) 2023-02-02
EP2703414A1 (en) 2014-03-05
EP2205635B1 (en) 2016-05-25
CN104231081B (zh) 2022-01-11
EA201000471A1 (ru) 2010-10-29
NO2022055I1 (no) 2022-12-09
PL2205635T3 (pl) 2016-12-30
SI2205635T1 (sl) 2016-09-30
CY1117702T1 (el) 2017-05-17
FR22C1059I2 (fr) 2023-12-22
EP3524622A1 (en) 2019-08-14
US10287348B2 (en) 2019-05-14
HUE028361T2 (en) 2016-12-28
LT2205635T (lt) 2016-09-26
TW201412774A (zh) 2014-04-01
AU2008300028B2 (en) 2014-12-18
LTPA2022016I1 (enExample) 2023-01-10
SG178781A1 (en) 2012-03-29
EP2205635A1 (en) 2010-07-14
DK2205635T3 (en) 2016-07-18
CY2022036I2 (el) 2023-03-24
KR20100067660A (ko) 2010-06-21
WO2009035577A1 (en) 2009-03-19
PH12017501025A1 (en) 2018-01-29
CN101809035A (zh) 2010-08-18
FR22C1059I1 (fr) 2023-02-03
AR068508A1 (es) 2009-11-18
EA201590631A1 (ru) 2016-03-31
EA022796B1 (ru) 2016-03-31
HK1145843A1 (zh) 2011-05-06
JP2019038843A (ja) 2019-03-14
CR11319A (es) 2010-04-21
TW200918554A (en) 2009-05-01
US20250154241A1 (en) 2025-05-15
CL2012003245A1 (es) 2013-03-22
CA2698382C (en) 2015-07-14
LUC00289I2 (enExample) 2025-05-12
MY150242A (en) 2013-12-31
NL301207I1 (nl) 2022-12-21
JP5956716B2 (ja) 2016-07-27
CL2008002668A1 (es) 2009-08-14
JP2024161358A (ja) 2024-11-19
JP2015091820A (ja) 2015-05-14

Similar Documents

Publication Publication Date Title
US20250154241A1 (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2074149B1 (en) Compositions and methods relating to glucagon receptor antibodies
AU2008330125A1 (en) Wise binding antibodies and epitopes
AU2014277673A1 (en) Antigen Binding Proteins Capable of Binding Thymic Stromal Lymphopoietin
HK40012723A (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
HK1195568A (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
HK1145843B (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20141021

Application number text: 1020107007193

Filing date: 20100401

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150626

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160104

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150626

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I